USD 9.1
(0.33%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 70.98 Million USD | -6.93% |
2022 | 76.27 Million USD | 2.18% |
2021 | 74.65 Million USD | 51.99% |
2020 | 49.11 Million USD | 41.83% |
2019 | 34.63 Million USD | 390.18% |
2018 | 7.06 Million USD | 0.0% |
2017 | - USD | -100.0% |
2016 | 47.5 Million USD | 55782.35% |
2015 | 85 Thousand USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 14.88 Million USD | -25.09% |
2024 Q2 | 20.49 Million USD | 37.7% |
2023 Q3 | 19.82 Million USD | 1.9% |
2023 Q4 | 19.86 Million USD | 0.21% |
2023 Q2 | 19.45 Million USD | 64.22% |
2023 FY | 70.98 Million USD | -6.93% |
2023 Q1 | 11.84 Million USD | -43.2% |
2022 Q4 | 20.85 Million USD | 3.87% |
2022 Q3 | 20.07 Million USD | -2.45% |
2022 Q2 | 20.58 Million USD | 39.44% |
2022 Q1 | 14.76 Million USD | -34.43% |
2022 FY | 76.27 Million USD | 2.18% |
2021 Q3 | 21.82 Million USD | 18.9% |
2021 Q2 | 18.35 Million USD | 53.49% |
2021 Q1 | 11.96 Million USD | -26.84% |
2021 FY | 74.65 Million USD | 51.99% |
2021 Q4 | 22.5 Million USD | 3.13% |
2020 Q4 | 16.34 Million USD | 5.9% |
2020 Q2 | 10.27 Million USD | 45.45% |
2020 Q3 | 15.43 Million USD | 50.27% |
2020 FY | 49.11 Million USD | 41.83% |
2020 Q1 | 7.06 Million USD | -36.27% |
2019 FY | 34.63 Million USD | 390.18% |
2019 Q2 | 6.67 Million USD | 49.17% |
2019 Q1 | 4.47 Million USD | 48.06% |
2019 Q4 | 11.08 Million USD | -10.62% |
2019 Q3 | 12.39 Million USD | 85.67% |
2018 Q1 | 865 Thousand USD | 0.0% |
2018 FY | 7.06 Million USD | 0.0% |
2018 Q4 | 3.02 Million USD | 58.94% |
2018 Q3 | 1.9 Million USD | 49.29% |
2018 Q2 | 1.27 Million USD | 47.28% |
2017 Q1 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 FY | - USD | -100.0% |
2016 FY | 47.5 Million USD | 55782.35% |
2016 Q2 | - USD | -100.0% |
2016 Q3 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q1 | 47.5 Million USD | 0.0% |
2015 FY | 85 Thousand USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 566.76 Million USD | 87.475% |
Embecta Corp. | 1.12 Billion USD | 93.666% |
ANI Pharmaceuticals, Inc. | 486.81 Million USD | 85.418% |
Dynavax Technologies Corporation | 232.28 Million USD | 69.44% |
Esperion Therapeutics, Inc. | 116.33 Million USD | 38.98% |
Pacira BioSciences, Inc. | 674.97 Million USD | 89.483% |
PainReform Ltd. | - USD | -Infinity% |
Aquestive Therapeutics, Inc. | 50.58 Million USD | -40.338% |
Sunshine Biopharma, Inc. | 24.09 Million USD | -194.64% |
SCYNEXIS, Inc. | 140.14 Million USD | 49.346% |
China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -3580.949% |
Cosmos Health Inc. | 53.37 Million USD | -32.992% |
Journey Medical Corporation | 79.18 Million USD | 10.348% |
Sunshine Biopharma, Inc. | 24.09 Million USD | -194.64% |
Safety Shot Inc | 202.67 Thousand USD | -34925.904% |
Alpha Teknova, Inc. | 36.68 Million USD | -93.509% |
Intra-Cellular Therapies, Inc. | 464.37 Million USD | 84.713% |
Bright Green Corporation | 401.49 Thousand USD | -17580.845% |
Procaps Group, S.A. | 409.92 Million USD | 82.683% |
Theratechnologies Inc. | 81.76 Million USD | 13.181% |
Harrow Health, Inc. | 130.19 Million USD | 45.476% |
Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -457.417% |
Biofrontera Inc. | 34.07 Million USD | -108.35% |
DURECT Corporation | 8.54 Million USD | -730.452% |
Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 88.315% |
Cronos Group Inc. | 88.84 Million USD | 20.096% |
Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 83.966% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
RedHill Biopharma Ltd. | 6.51 Million USD | -989.899% |
Organogenesis Holdings Inc. | 433.14 Million USD | 83.611% |
Guardion Health Sciences, Inc. | 12.24 Million USD | -479.554% |
Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -79.475% |
Radius Health, Inc. | 2.88 Billion USD | 97.537% |
Universe Pharmaceuticals INC | 32.3 Million USD | -119.715% |
ProPhase Labs, Inc. | 44.38 Million USD | -59.938% |
Phibro Animal Health Corporation | 1.01 Billion USD | 93.025% |
Procaps Group S.A. | 409.92 Million USD | 82.683% |
Alvotech | 91.43 Million USD | 22.363% |
TherapeuticsMD, Inc. | 1.3 Million USD | -5352.151% |
Viatris Inc. | 15.42 Billion USD | 99.54% |
Rockwell Medical, Inc. | 83.61 Million USD | 15.1% |
Aytu BioPharma, Inc. | 81 Million USD | 12.364% |
SIGA Technologies, Inc. | 139.91 Million USD | 49.265% |
Tilray Brands, Inc. | 788.94 Million USD | 91.002% |
Lifecore Biomedical, Inc. | 128.26 Million USD | 44.654% |
Shineco, Inc. | 9.8 Million USD | -624.22% |
PetIQ, Inc. | 1.1 Billion USD | 93.558% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Incannex Healthcare Limited | 12 Thousand USD | -591458.333% |
Neurocrine Biosciences, Inc. | 1.88 Billion USD | 96.238% |
Alimera Sciences, Inc. | 80.75 Million USD | 12.095% |
Silver Spike Investment Corp. | 11.72 Million USD | -505.581% |
Assertio Holdings, Inc. | 152.06 Million USD | 53.319% |
Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Petros Pharmaceuticals, Inc. | 5.82 Million USD | -1119.208% |
Clever Leaves Holdings Inc. | 17.41 Million USD | -307.573% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | -6494.823% |
Avadel Pharmaceuticals plc | 27.96 Million USD | -153.86% |
Hempacco Co., Inc. | 4.04 Million USD | -1654.656% |
Talphera, Inc. | 651 Thousand USD | -10804.301% |
Alvotech | 91.43 Million USD | 22.363% |
Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 77.579% |
Lantheus Holdings, Inc. | 1.29 Billion USD | 94.524% |
Currenc Group, Inc. | 53.25 Million USD | -33.296% |
Kamada Ltd. | 144.75 Million USD | 50.962% |
Indivior PLC | 1.09 Billion USD | 93.505% |
Evoke Pharma, Inc. | 5.18 Million USD | -1270.239% |
Flora Growth Corp. | 76.07 Million USD | 6.683% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | -6494.823% |
Evolus, Inc. | 202.08 Million USD | 64.873% |
HUTCHMED (China) Limited | 837.99 Million USD | 91.529% |
Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 88.984% |
Akanda Corp. | 2.16 Million USD | -3186.356% |